Cyclerion Therapeutics Inc (OQ:CYCN)

Business Focus: Biotechnology & Medical Research

Jun 11, 2019 04:30 am ET
Cyclerion Therapeutics to Present Preclinical Data on its Clinical-Stage sGC Stimulators for Neurodegenerative and Cardiometabolic Diseases at the 9th International Conference on cGMP
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that three upcoming data presentations...
Jun 04, 2019 04:30 am ET
Cyclerion Therapeutics to Present Data on its Sickle Cell Disease Program at Upcoming Medical and Scientific Meetings
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced upcoming data presentations supporting...
May 13, 2019 03:00 am ET
Cyclerion Therapeutics Provides a Corporate and Pipeline Overview as a Newly Launched Public Biopharmaceutical Company
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today provided a general corporate...
Apr 25, 2019 04:00 am ET
Cyclerion to Host Corporate Overview Call on May 13, 2019
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it will host a...
Apr 09, 2019 04:00 am ET
Cyclerion Announces the Appointment of Andreas Busch, Ph.D., as Chief Innovation Officer
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that Andreas (Andy)...
Apr 02, 2019 04:00 am ET
Cyclerion Launches as Clinical-Stage Biopharmaceutical Company Harnessing the Power of Soluble Guanylate Cyclase (sGC) Pharmacology for Treatment of Serious and Orphan Diseases
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced its launch as an independent, publicly traded clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and...
Apr 01, 2019 12:02 pm ET
Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that it has completed the tax-free spin-off of its soluble guanylate cyclase (sGC) business, Cyclerion Therapeutics, Inc. (Cyclerion).